F M Veronese

Summary

Affiliation: University of Padova
Country: Italy

Publications

  1. ncbi The impact of PEGylation on biological therapies
    Francesco M Veronese
    Department of Pharmaceutical Sciences, Padua University, Padua, Italy
    BioDrugs 22:315-29. 2008
  2. ncbi Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation
    Francesco M Veronese
    Department of Pharmaceutical Sciences, University of Padova, 5, Via Marzolo, 35100 Padova, Italy
    Adv Drug Deliv Rev 54:587-606. 2002
  3. ncbi Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin
    Andrea Guiotto
    Department of Pharmaceutical Sciences, University of Padova, Via F Marzolo, 5, 35131 Padova, Italy
    J Med Chem 47:1280-9. 2004
  4. ncbi PEGylation: Posttranslational bioengineering of protein biotherapeutics
    Francesco M Veronese
    Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo 5, 35131 Padua, Italy Electronic
    Drug Discov Today Technol 5:e57-64. 2008
  5. ncbi PEGylation, successful approach to drug delivery
    Francesco M Veronese
    Department of Pharmaceutical Sciences, Padua University, Italy
    Drug Discov Today 10:1451-8. 2005
  6. ncbi PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity
    Francesco M Veronese
    Department of Pharmaceutical Science, University of Padua, Via F Marzolo 5, 35100 Padua, Italy
    Bioconjug Chem 16:775-84. 2005
  7. ncbi Site-specific pegylation of G-CSF by reversible denaturation
    Francesco M Veronese
    Department of Pharmaceutical Science, University of Padua, Via Marzolo 5, 35100, Padua, Italy
    Bioconjug Chem 18:1824-30. 2007
  8. ncbi Pegylated enzyme entrapped in poly(vinyl alcohol) hydrogel for biocatalytic application
    F M Veronese
    Department of Pharmaceutical Sciences, University of Padua, Center of Chemical Investigation of Drugs CNR, Italy
    Farmaco 56:541-7. 2001
  9. ncbi Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers
    P Caliceti
    Department of Pharmaceutical Sciences, University of Padova, Via F Marzolo 5, 35131 Padova, Italy
    Bioconjug Chem 10:638-46. 1999
  10. doi Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery
    M Canevari
    Department of Pharmaceutical Sciences, University of Padova, Via Francesco Marzolo 5, 35131 Padova, Italy
    Int J Pharm 368:171-7. 2009

Collaborators

Detail Information

Publications49

  1. ncbi The impact of PEGylation on biological therapies
    Francesco M Veronese
    Department of Pharmaceutical Sciences, Padua University, Padua, Italy
    BioDrugs 22:315-29. 2008
    ..The adaptations and applications of PEGylation will undoubtedly prove useful for the treatment of many previously difficult-to-treat conditions...
  2. ncbi Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation
    Francesco M Veronese
    Department of Pharmaceutical Sciences, University of Padova, 5, Via Marzolo, 35100 Padova, Italy
    Adv Drug Deliv Rev 54:587-606. 2002
    ..In view of so much positive research on PEG-SOD, it is surprising that no approved application in human therapy has been established and approved...
  3. ncbi Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin
    Andrea Guiotto
    Department of Pharmaceutical Sciences, University of Padova, Via F Marzolo, 5, 35131 Padova, Italy
    J Med Chem 47:1280-9. 2004
    ..Pharmacokinetic studies indicated that 3 acts as a reservoir of 10-amino-7-ethylcamptothecin, as the mean residence time (MRT) is about 3-fold higher than that of the free drug...
  4. ncbi PEGylation: Posttranslational bioengineering of protein biotherapeutics
    Francesco M Veronese
    Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo 5, 35131 Padua, Italy Electronic
    Drug Discov Today Technol 5:e57-64. 2008
    ..So far, PEGylation has already led to nine marketed conjugates with great therapeutic success.: ..
  5. ncbi PEGylation, successful approach to drug delivery
    Francesco M Veronese
    Department of Pharmaceutical Sciences, Padua University, Italy
    Drug Discov Today 10:1451-8. 2005
    ..Thanks to these favorable properties, PEGylation now plays an important role in drug delivery, enhancing the potentials of peptides and proteins as therapeutic agents...
  6. ncbi PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity
    Francesco M Veronese
    Department of Pharmaceutical Science, University of Padua, Via F Marzolo 5, 35100 Padua, Italy
    Bioconjug Chem 16:775-84. 2005
    ..Further studies are warranted with PEG5000(L)-GFLG-Dox to determine its spectrum of antitumor activity and also the optimum dosing schedule before clinical testing...
  7. ncbi Site-specific pegylation of G-CSF by reversible denaturation
    Francesco M Veronese
    Department of Pharmaceutical Science, University of Padua, Via Marzolo 5, 35100, Padua, Italy
    Bioconjug Chem 18:1824-30. 2007
    ..Unexpectedly, conjugation enhanced the G-CSF tendency to aggregate, a problem that was overcome by a proper formulation...
  8. ncbi Pegylated enzyme entrapped in poly(vinyl alcohol) hydrogel for biocatalytic application
    F M Veronese
    Department of Pharmaceutical Sciences, University of Padua, Center of Chemical Investigation of Drugs CNR, Italy
    Farmaco 56:541-7. 2001
    ....
  9. ncbi Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers
    P Caliceti
    Department of Pharmaceutical Sciences, University of Padova, Via F Marzolo 5, 35131 Padova, Italy
    Bioconjug Chem 10:638-46. 1999
    ..7) Finally, all the enzyme forms slowly disposed in kidneys with higher levels for the poly(N-acryloilmorpholine) derivative (15% after 2880 min) and unmodified uricase (14% after 1440 min)...
  10. doi Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery
    M Canevari
    Department of Pharmaceutical Sciences, University of Padova, Via Francesco Marzolo 5, 35131 Padova, Italy
    Int J Pharm 368:171-7. 2009
    ..The results in vivo take into consideration mice bodyweight gain, tissue histology and interleukin-2 beta as an index of inflammation. These parameters, all together, demonstrated the conjugate effectiveness against the controls...
  11. ncbi Polyorganophosphazene microspheres for drug release: polymer synthesis, microsphere preparation, in vitro and in vivo naproxen release
    F M Veronese
    Department of Pharmaceutical Sciences, Centro di Studio di Chimica del Farmaco e dei Prodotti Biologicamente Attivi del CNR, University of Padova, Italy
    J Control Release 52:227-37. 1998
    ....
  12. ncbi Covalent modification of mushroom tyrosinase with different amphiphic polymers for pharmaceutical and biocatalysis applications
    M Morpurgo
    Department of Pharmaceutical Sciences, Biologicamente Attivi del CNR, University of Padova, Italy
    Appl Biochem Biotechnol 56:59-72. 1996
    ..However, organic solvent solubilization brought about loss of enzyme conformation as assessed by CD measurements, which is accompanied by a nonreversible loss of catalytic activity...
  13. ncbi New PEGs for peptide and protein modification, suitable for identification of the PEGylation site
    F M Veronese
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
    Bioconjug Chem 12:62-70. 2001
    ..Mass spectrometry, amino acid analysis and Edman sequence, could reveal the position of the reporter norleucine that corresponds to the position of PEG binding...
  14. ncbi Immunological properties of uricase conjugated to neutral soluble polymers
    P Caliceti
    Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo, 5 Padova, Italy
    Bioconjug Chem 12:515-22. 2001
    ....
  15. ncbi PEG-Ara-C conjugates for controlled release
    O Schiavon
    Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo 5, 35131 Padua, Italy
    Eur J Med Chem 39:123-33. 2004
    ..Increased stability towards degradation of the conjugated Ara-C products, in particular for the highly loaded ones, improved blood residence time in mice and a reduced cytotoxicity with respect to the free Ara-C form was demonstrated...
  16. ncbi Polyphosphazene microspheres for insulin delivery
    P Caliceti
    Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo, 5, 35131, Padova, Italy
    Int J Pharm 211:57-65. 2000
    ..Finally all preparations stimulated anti-insulin antibody production that constantly increased over a period of 8 weeks...
  17. ncbi Synthesis and biopharmaceutical characterisation of new poly(hydroxyethylaspartamide) copolymers as drug carriers
    P Caliceti
    Dipartimento di Scienze Farmaceutiche, , Padua, Italy
    Biochim Biophys Acta 1528:177-86. 2001
    ..In particular, the poly(ethylene glycol)/hexadecylalkyle conjugates achieved a concentration of 15-25% of the dose/g of tissue after 24 h from administration that was maintained up to 144 h...
  18. ncbi Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake
    Manuela Berna
    Department of Pharmaceutical Science, University of Padua, Via Marzolo 5, 35100 Padua, Italy
    Biomacromolecules 7:146-53. 2006
    ..These well-defined novel architectures have potential for further development as targetable drug delivery systems or tools for construction of structurally defined modified surfaces...
  19. ncbi Immunogenic and tolerogenic properties of monomethoxypoly(ethylene glycol) conjugated proteins
    P Caliceti
    Department of Pharmaceutical Sciences, University of Padova, Italy
    Farmaco 54:430-7. 1999
    ..Such suppression depended on the degree of modification: the conjugate with the higher number of polymer chains was more effective in suppressing the immunoresponse...
  20. ncbi Purification, modification, physico-chemical and pharmacokinetic characterization of arginase, an enzyme of potential use in therapy
    C Visco
    Department of Pharmaceutical Sciences, University of Padova, Italy
    Farmaco Sci 42:549-59. 1987
    ....
  21. ncbi Synthesis and characterization of high-molecular mass polyethylene glycol-conjugated oligonucleotides
    G M Bonora
    Pharmaco Chemico Technology Department, University of Cagliari, Italy
    Bioconjug Chem 8:793-7. 1997
    ..The PEG-conjugated 12mer was efficiently synthesized and purified. It was found that the high-molecular mass PEG chain results in enzymatic stability and does not interfere with the formation of the duplex with its nucleic acid target...
  22. ncbi Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase
    Angelo Fontana
    CRIBI Biotechnology Centre, Viale G Colombo 3, University of Padua, 35121 Padua, Italy
    Adv Drug Deliv Rev 60:13-28. 2008
    ....
  23. ncbi Second-Generation Pharmaceutical Proteins-EUFEPS Workshop on Optimizing Biotech Medicines
    Gianfranco Pasut
    University of Padua, Department of Pharmaceutical Sciences, Via F Marzolo 5, 35128 Padua, Italy
    IDrugs 10:162-4. 2007
  24. ncbi Anti-cancer PEG-enzymes: 30 years old, but still a current approach
    Gianfranco Pasut
    Department of Pharmaceutical Sciences, University of Padua, Via Marzolo 5, 35100 Padua, Italy
    Adv Drug Deliv Rev 60:69-78. 2008
    ..Here, we describe some examples of PEGylated enzymes useful in antitumoral therapies and the most recent advances in this field...
  25. doi PEGylation for improving the effectiveness of therapeutic biomolecules
    Gianfranco Pasut
    Department of Pharmaceutical Sciences, University of Padua, Padua, Italy
    Drugs Today (Barc) 45:687-95. 2009
    ..This feature enables the recovery of the protein activity that is commonly reduced after polymer coupling...
  26. ncbi Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates?
    Anna Mero
    Department of Pharmaceutical Sciences, University of Padua, Via Marzolo 5, Padua 35128, Italy
    J Control Release 125:87-95. 2008
    ..These data support the potential of POZ as a versatile alternative to the well-known and widely used PEG for protein and drug conjugation and delivery...
  27. doi Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid
    Gianfranco Pasut
    Pharmaceutical Sciences Department, University of Padua, Via F Marzolo 5, 35143 Padua, Italy
    J Control Release 127:239-48. 2008
    ..These results are promising and encourage in vivo studies on these conjugates that act as polymeric prodrugs...
  28. ncbi Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action
    Gianfranco Pasut
    Department of Pharmaceutical Sciences, Via F Marzolo 5, University of Padua, 35100 Padova, Italy
    J Med Chem 52:6499-502. 2009
    ..FACS and confocal microscopy confirmed conjugates internalization. Light scattering showed formation of micelle whose size correlated with internalization rate. EPI-PEG-(NO)8 showed increased bioavailability in mice compared to free EPI...
  29. doi PEG conjugates in clinical development or use as anticancer agents: an overview
    Gianfranco Pasut
    Department of Pharmaceutical Sciences, University of Padua, Via Marzolo 5, 35100 Padova, Italy
    Adv Drug Deliv Rev 61:1177-88. 2009
    ..Interestingly, PEGylated conjugates have been also considered as adjuvant therapy in many standard anticancer protocols, in this regard the case of PEG-G-CSF and PEG-interferons will be presented...
  30. ncbi A new PEG-beta-alanine active derivative for releasable protein conjugation
    Gianfranco Pasut
    Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo 5, 35131 Padua, Italy
    Bioconjug Chem 19:2427-31. 2008
    ..The conjugate potency was evaluated in hypophysectomized rats demonstrating a superior pharmacodynamic profile with respect to native hGH...
  31. ncbi Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
    Paolo Caliceti
    Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo 5, 35131 Padova, Italy
    Adv Drug Deliv Rev 55:1261-77. 2003
    ..The examples reported in this review show that general considerations could be useful in developing a target product, although significant deviations from the expected results can not be excluded...
  32. ncbi Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting
    Paolo Caliceti
    Department of Pharmaceutical Sciences, University of Padova, Via F Marzolo 5, 35131 Padova, Italy
    J Control Release 83:97-108. 2002
    ..In particular, in the case of avidin-PEG 20 kDa, 8% of the injected dose (ID)/g of tissue accumulated in the tumor after 5 h from the administration and over 6% of the ID/g was maintained throughout 72 h...
  33. ncbi Selective alkylation and acylation of alpha and epsilon amino groups with PEG in a somatostatin analogue: tailored chemistry for optimized bioconjugates
    Margherita Morpurgo
    Universita degli Studi di Padova, Dipartimento Scienze Farmaceutiche, Via Marzolo, 5, 35131 Padova, Italy
    Bioconjug Chem 13:1238-43. 2002
    ..The results obtained suggest the importance of preliminary studies in the development of new polymer-peptide conjugates with improved pharmacological properties...
  34. ncbi Synthesis, characterization and preliminary cytotoxicity assays of poly(ethylene glycol)-malonato-Pt-DACH conjugates
    Alessia Furin
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Padova, Via F Marzolo, 5 35100, Padua, Italy
    Eur J Med Chem 38:739-49. 2003
    ..The compound PEG(5000)-Nle-malonato-Pt-DACH (4) has been tested against L1210-implanted mice and showed and appreciable increase in cytotoxicity as compared to the reference standard Cl(2)PtDACH...
  35. ncbi Efficient and chemoselective N-acylation of 10-amino-7-ethyl camptothecin with poly(ethylene glycol)
    Andrea Guiotto
    Department of Pharmaceutical Sciences, University of Padova via F Marzolo, 5 35131 Padova, Italy
    Bioorg Med Chem Lett 14:1803-5. 2004
    ..The conjugate was tested against P388 murine leukemia cell lines and resulted equipotent to CPT-11, a camptothecin analogue already in clinical use...
  36. ncbi Peptide and protein PEGylation: a review of problems and solutions
    F M Veronese
    Department of Pharmaceutical Sciences, CNR, Center for Chemical Investigation of Drugs, University of Padova, Italy
    Biomaterials 22:405-17. 2001
    ..Finally, the paper reports on more specific methods regarding reversible PEGylation, cross-linking reagents with PEG arms, PEG for enzyme solubilization in organic solvent and new polymers as alternative to PEG...
  37. ncbi Synthesis and biological in vitro evaluation of novel PEG-psoralen conjugates
    F Bettio
    Department of Pharmaceutical Sciences, University of Padua, Via Francesco Marzolo 5, 35131 Padova, Italy
    Biomacromolecules 7:3534-41. 2006
    ..Conjugate 12 appears to be the most promising for future in vivo evaluation, since it was relatively stable in plasma, which should allow tumor targeting and drug release to occur by cathepsin B-mediated hydrolysis...
  38. ncbi Slow release of two antibiotics of veterinary interest from PVA hydrogels
    A Moretto
    Department of Pharmaceutical Sciences, University of Padova, Via Marzolo, 5, 35131, Padova, Italy
    Farmaco 59:1-5. 2004
    ..Oxytetracycline could also be quantitatively entrapped and released from PVA hydrogels, but once administered per os to rats, it was not detected in blood or organs...
  39. ncbi Conjugates of peptides and proteins to polyethylene glycols
    Margherita Morpurgo
    Pharmaceutical Sciences Department, University of Padova, Italy
    Methods Mol Biol 283:45-70. 2004
    ..Methods for product purification and characterization are also provided. The overall information provided will guide the reader toward all of the critical steps involved in the preparation of PEG-protein adducts...
  40. ncbi An improved procedure for the synthesis of branched polyethylene glycols (PEGs) with the reporter dipeptide Met-betaAla for protein conjugation
    Andrea Guiotto
    Dipartimento di Science Farmaceutiche, Via Marzolo 5, 35100 Padova, Italy
    Bioorg Med Chem Lett 12:177-80. 2002
    ....
  41. doi Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG
    Anna Mero
    CRIBI Biotechnology Centre, University of Padua, Viale G Colombo 3, 35121 Padua, Italy
    Bioconjug Chem 20:384-9. 2009
    ....
  42. ncbi Bioconjugation in pharmaceutical chemistry
    F M Veronese
    Department of Pharmaceutical Sciences, University of Padua, Italy
    Farmaco 54:497-516. 1999
    ..Bioconjugation developed also the design of new tailor-made polymers with the wanted molecular weight, shape, structure and with the functional groups needed for coupling at the wanted positions in the chain...
  43. ncbi Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation
    Andrea Guiotto
    Dipartimento di Science Farmaceutiche, Via Marzolo, 5, 35131 Padova, Italy
    Bioorg Med Chem 12:5031-7. 2004
    ..Unexpected results reveal an anchimeric assistance of the Lys-AaA amide proton to the hydrolysis of the carbamoyl moiety joining mPEG to the alpha-amino group of lysine through the formation of an hydantoin system...
  44. doi Detection of sites of infection in mice using 99mTc-labeled PN(2)S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study
    Laura Meléndez-Alafort
    Department of Pharmaceutical Sciences, University of Padua, 35131 Padova, Italy
    Nucl Med Biol 36:57-64. 2009
    ....
  45. ncbi PEGylation of the antimicrobial peptide nisin A: problems and perspectives
    Andrea Guiotto
    Dipartimento di Science Farmaceutiche, Padua, Italy
    Farmaco 58:45-50. 2003
    ..We report the synthesis of a PEG-nisin conjugate, and the microbiology assays against some bacterial cell lines...
  46. ncbi Introduction and overview of peptide and protein pegylation
    Francesco M Veronese
    Adv Drug Deliv Rev 54:453-6. 2002
  47. ncbi Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates
    Lars Andersson
    PolyPeptide Laboratories Sweden AB, PO Box 30089, SE 20061 Limhamn, Sweden
    Biomacromolecules 6:914-26. 2005
    ..However, the successful scale-up synthesis of DBM2-PEG4000-S-PEG3000 constructs suggest that they are worthy of further investigation as carriers for controlled release and targeting of less hydrophobic agents...
  48. ncbi Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice
    Luca Santucci
    Struttura Complessa di Gastroenterologia, Azienda Ospedaliera di Perugia, Italy
    Anticancer Drugs 18:1081-91. 2007
    ..The present data provide evidence that addition of a nitric oxide-releasing moiety to pegylated epirubicin confers a new and unique cytotoxic profile to the drug...
  49. ncbi Histaminase PEGylation: preparation and characterization of a new bioconjugate for therapeutic application
    Rodolfo Federico
    Department of Biology, University of Roma Tre, Italy
    J Control Release 115:168-74. 2006
    ..The considerable ease of native histaminase production as well as the improved properties after PEGylation, make this engineered plant enzyme a suitable drug candidate for alternative treatment of histamine-mediated affections...